Executive Summary: Key Legal and Evidentiary Issues

• Apotex sought damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations after Eli Lilly’s prohibition application was dismissed.

• The trial judge ruled Apotex failed to prove it would and could have entered the market during the relevant period in the hypothetical “no prohibition application” world.

• The appeal addressed whether the trial judge misapplied the legal test for causation and improperly rejected Apotex’s hypothetical market evidence.

• Eli Lilly argued Apotex’s claim was speculative and lacked supporting facts about regulatory and commercial readiness.

• The Court of Appeal emphasized deference to factual findings and upheld the trial judge’s conclusions as reasonable and based on the evidence.

• The appeal was dismissed, and Apotex’s claim for section 8 damages was denied.

Facts and lower court ruling

This case arose from a claim by Apotex Inc. for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations after Eli Lilly’s application for an order prohibiting Apotex from receiving a Notice of Compliance was dismissed. Section 8 allows a generic manufacturer to recover damages for lost sales in the period it was kept off the market due to an unsuccessful prohibition proceeding. At trial, Apotex was required to prove that it would and could have entered the market during the “Relevant Period” had there been no prohibition application.

The trial judge found Apotex failed to meet that burden. While Apotex claimed it would have launched its generic atomoxetine product, the judge concluded Apotex did not establish the factual foundation necessary to support this assertion. The court found that Apotex had not proven it would have launched in a but-for world, nor that it could have, due to a lack of necessary regulatory, commercial, and manufacturing readiness.

Issues on appeal

On appeal, Apotex argued that the trial judge erred in his interpretation and application of section 8, particularly by applying a stricter causation standard than required and by misapprehending the hypothetical market analysis. Apotex contended that the trial judge ignored credible expert evidence about generic market behavior and improperly relied on factual findings that were not supported by the record.

Eli Lilly defended the trial ruling, stating the judge had properly applied the test and made factual findings that were open to him based on the evidence. The company emphasized that the hypothetical scenario required a specific and credible evidentiary foundation, which Apotex had failed to provide.

Court of Appeal’s analysis and decision

The Ontario Court of Appeal dismissed the appeal. The Court held that the trial judge applied the correct legal test for determining damages under section 8. Specifically, the test required Apotex to demonstrate both its intent and capacity to launch its generic product during the Relevant Period. The Court found that the trial judge's findings—namely, that Apotex lacked sufficient evidence to prove it would or could have launched in that time—were reasonable and entitled to deference.

The Court rejected the suggestion that the judge had raised the evidentiary bar. It found no error in the conclusion that Apotex had not proven that it had the necessary regulatory approvals, manufacturing capability, or strategic intent to launch atomoxetine in the hypothetical world.

Conclusion

The appeal was dismissed with costs. Apotex failed to establish entitlement to damages under section 8 of the PM(NOC) Regulations, reaffirming that claimants must present robust and credible evidence when constructing hypothetical market scenarios to support damages claims in pharmaceutical litigation.